Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
- Conditions
- Advanced Locoregional MelanomaMetastatic MelanomaMetastatic Renal Cell CarcinomaClear Cell Histology
- Interventions
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 78
- Registration Number
- NCT05155033
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Ciclosporin Followed by Low-dose IL-2 in Patients with Recently Diagnosed Type 1 Diabetes
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 24
- Registration Number
- NCT05153070
- Locations
- 🇫🇷
Lorenzon Roberta, Paris, France
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
- Conditions
- Metastatic HPV-16 Positive Squamous Cell Anal Cancer
- Interventions
- Biological: Individual Patient TCR-Transduced PBL
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT04536922
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
- Conditions
- Cancer, GastrointestinalGall Bladder CancerStomach CancerGastrointestinal Epithelial CancerGastrointestinal NeoplasmsCancer of Gastrointestinal TractGastrointestinal CancerPancreatic CancerColo-rectal CancerColon Cancer
- Interventions
- Biological: Tumor-Infiltrating Lymphocytes (TIL)
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Intima Bioscience, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04426669
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients
- Conditions
- Metastatic Urothelial Carcinoma
- Interventions
- Procedure: Tumor Infiltrating Lymphocytes (TIL)
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT04383067
- Locations
- 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19
- Conditions
- COVID 19
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 30
- Registration Number
- NCT04357444
- Locations
- 🇫🇷
Service Anesthésie Réanimation - Groupe Hospitalier Pitié-Salpêtrière, Paris, France
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 15
- Registration Number
- NCT04133233
- Locations
- 🇫🇷
Pr Marion Leboyer, Créteil, Hôpital Albert Chenevier, France
Non-Viral TCR Gene Therapy
- Conditions
- Non-Small Cell Lung CancerBreast CancerEndocrine/NeuroendocrineGastrointestinal/Genitourinary CancersOvarian Cancer
- Interventions
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT04102436
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 40
- Registration Number
- NCT03837093
- Locations
- 🇫🇷
Clinical Investigation Center Paris Est Hôpital Universitaire Pitié-Salpêtrière 83 bd de l'Hôpital 75013 Paris, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.